Spinal Muscular Atrophy Financial Planning: Medicaid Preservation, Treatment Costs, and SNT Strategy

Spinal muscular atrophy is the genetic disease where the financial stakes have changed most dramatically in the last decade. Before 2017, SMA Type 1 was the leading genetic cause of infant death. Today, three FDA-approved treatments — Spinraza, Evrysdi, and Itvisma — can dramatically slow or halt disease progression. But those treatments cost $375,000 per year (Spinraza), $340,000 per year (Evrysdi), or $2.59 million as a one-time dose (Itvisma, approved November 2025 for patients ages 2 and older). For any SMA family, Medicaid preservation is not one goal among many. It is the financial planning foundation on which everything else rests — because Medicaid is the primary payer for the treatment that keeps the disease from progressing.

SMA types and financial planning implications

SMA is caused by a deletion or mutation in the SMN1 gene. All four types share the same genetic cause; the distinction is age of onset and functional severity.¹

The three treatments and why Medicaid is the financial plan

Before 2017, there were no disease-modifying treatments for SMA. Today there are three, and the cost of each makes Medicaid preservation the dominant financial planning objective for any SMA family.

Spinraza (nusinersen) — $750K year 1, $375K/year ongoing

Spinraza, developed by Biogen and approved by FDA in December 2016, was the first treatment for SMA. It is delivered by intrathecal injection — a lumbar puncture — every 4 months after an initial loading series. The list price is approximately $125,000 per injection, with 6 loading doses in the first year ($750,000) and 3 maintenance doses per year thereafter ($375,000 annually).²

Spinraza is approved for all ages and all SMA types. It is currently the most widely used SMA treatment globally, in part because it is accessible to patients who received gene therapy as infants and need ongoing therapy as adults — a population for which the one-time gene therapies were not originally indicated.

Evrysdi (risdiplam) — up to $340K/year, oral

Evrysdi, developed by Roche and PTC Therapeutics and approved in August 2020, is an oral liquid taken daily at home. It is weight-based and priced below the cap of $340,000 per year for lighter patients, with pricing capped at the maximum for patients above approximately 44 pounds — meaning most adults pay the full annual cost.³ The oral delivery makes Evrysdi a practical alternative for patients who cannot tolerate lumbar punctures or who prefer home administration. It is approved for ages 2 months and older, all SMA types.

Itvisma — $2.59M one-time, for ages 2 and older (FDA approved November 2025)

Itvisma (onasemnogene abeparvovec-brve), developed by Novartis, is an intrathecal gene replacement therapy FDA-approved on November 24, 2025, for children 2 years and older, adolescents, and adults with a confirmed SMN1 gene mutation — regardless of SMA type or prior treatment history.⁴ It delivers a functional copy of the SMN1 gene directly into the cerebrospinal fluid via a single spinal injection. The one-time list price is $2.59 million.

Itvisma is distinct from Zolgensma (the original IV gene therapy approved in 2019 for children under 2, priced at $2.125 million), which uses a different delivery route and is limited to the youngest patients. Itvisma's intrathecal delivery extends gene therapy to the much larger population of older children and adults who were not eligible for Zolgensma. Novartis offers an outcomes-based payment program that spreads the cost over 5 years — but even the annual payment ($518,000/year) exceeds Spinraza's maintenance cost. Medicaid coverage decisions for Itvisma are still being determined state-by-state as of mid-2026.

Why Medicaid is the access gate

Commercial insurance typically covers these treatments after prior authorization, but coverage can be disrupted by job change, employer plan change, or loss of employment. Medicaid — when maintained — provides a floor of coverage that is not employment-dependent. For a person on SSI who qualifies for Medicaid automatically (in 1634 states), the SSI-Medicaid connection is the most valuable financial asset in the plan.

The critical planning rule: never let a resource or income event destroy SSI eligibility without first confirming the Section 1619(b) protection applies. A $10,000 inheritance deposited in the wrong account can eliminate SSI — and immediately trigger Medicaid disqualification, cutting off access to Spinraza or Evrysdi. The financial plan must be constructed so this cannot happen accidentally.

SSDI and Social Security disability benefits

Types 0 and 1: Compassionate Allowance fast-track

SMA Types 0 and 1 are included on SSA's Compassionate Allowances (CAL) list, which enables disability determinations in approximately 10 days with sufficient medical documentation.⁵ CAL is not automatic — the applicant must still file an SSDI or SSI claim and provide the SMA diagnosis with genetic confirmation (SMN1 deletion/mutation). But once the documentation is provided, the processing time is dramatically compressed compared to the standard 3–6 month evaluation.

For infants diagnosed via newborn screening (see below), SSI should be applied for immediately after diagnosis — even before symptoms appear. SSI eligibility for a child is income-and-resource-means-tested on the parents' finances until age 18, but establishing the application creates a record and begins the Medicaid eligibility timeline. A benefits counselor can calculate whether the child's SSI will be $0 based on parental income; this is common for middle- and upper-income families. But the Medicaid that attaches to SSI eligibility — even with $0 cash benefit — is worth preserving, because Medicaid is often the primary payer for Spinraza or Evrysdi even when the family has commercial insurance as a secondary payer.

Types 2 and 3: standard evaluation under functional motor criteria

SMA Types 2 and 3 are not on the CAL list and are not evaluated under a single specific Blue Book listing. Instead, SSA evaluates them under the neurological listings (Section 11.00) based on their effects on motor functioning, respiratory function, and physical and mental limitations.⁶ A non-ambulatory Type 2 adult with documented upper and lower extremity weakness, respiratory involvement, and inability to perform sedentary work tasks will typically qualify — but the evaluation follows standard processing time (3–6 months), not the CAL fast-track.

Type 3 adults who work and are functional at the time of application may not qualify for SSDI if their current earnings and functional capacity remain above the threshold. The planning question is whether to file proactively as function declines, or to continue working under Section 1619(b) protections. A benefits counselor who understands SMA's natural history — particularly the risk of losing ambulation — should model both timelines explicitly.

Disabled Adult Child (DAC) benefits

An adult with SMA Types 0, 1, or 2 whose disability onset was before age 22 can receive Social Security benefits on a parent's earnings record when that parent retires, becomes disabled, or dies. DAC benefits are typically 50% of the parent's Primary Insurance Amount (PIA) while the parent is living and 75% when the parent has died.⁷ For a parent who earned $80,000–$120,000 per year throughout their career, DAC benefits commonly reach $1,500–$2,800 per month — substantially above the SSI Federal Benefit Rate of $994/month.

DAC benefits trigger Medicare after a 24-month waiting period, which can supplement or replace Medicaid as the insurance payer for SMA treatments. The SSI-to-DAC transition requires careful planning: DAC income may reduce or eliminate SSI cash benefits, but Section 1619(b) can protect Medicaid when DAC income is above the SSI break-even but below the state threshold. A benefits specialist should model the DAC election timing relative to treatment access.

Section 1619(b): the working adult's protection

For SMA Type 3 and Type 4 adults who receive SSI and continue working, Section 1619(b) is the most critical financial protection to understand. It allows an SSI beneficiary to earn above the Substantial Gainful Activity level ($1,690/month in 2026) and have their SSI cash benefit reduced to zero — while retaining full Medicaid coverage.⁸

The protection applies as long as the person's earnings are below their state's 1619(b) threshold, which varies substantially:

A person whose earnings exceed their state's standard threshold may still qualify through an individualized threshold calculation that factors in Impairment-Related Work Expenses (IRWEs — transportation, personal care attendant at work, wheelchair maintenance), paid attendant care, and medical expenses. For an SMA Type 3 adult with high IRWE from mobility equipment and attendant services, the individualized threshold can be substantially higher than the state standard.

Before accepting any raise, bonus, or new position that would significantly increase earnings, an SMA beneficiary on SSI should consult a Work Incentive Planning and Assistance (WIPA) counselor. An earnings increase that pushes past the state threshold without triggering the individualized calculation can cause unintended Medicaid termination — and a $375,000/year Spinraza prescription does not survive a six-month Medicaid coverage gap.

Newborn screening: the plan starts at birth

SMA was added to the federal Recommended Uniform Screening Panel (RUSP) in July 2018. As of 2026, all 50 states and the District of Columbia include SMA in their newborn screening programs.¹ This means many infants are now diagnosed presymptomatically — before any motor symptoms appear — which dramatically improves treatment outcomes when gene therapy is administered before motor neuron loss begins.

A positive SMA newborn screen triggers an urgent financial planning sequence that most new parents are not prepared for:

1. File for SSI and Medicaid immediately. Even if the family's income makes the SSI cash benefit $0, the Medicaid that attaches to SSI eligibility may be the coverage that pays for Zolgensma ($2.125M) or, for older infants, Itvisma ($2.59M) or Spinraza ($750K year 1). A special needs planning attorney and a WIPA benefits counselor should be engaged within the first weeks after diagnosis — before the treatment decision is made.
2. Do not deposit any gifts or insurance proceeds in the child's name. A 529 account, UGMA/UTMA account, or direct inheritance in the child's name counts as a resource. If it exceeds $2,000, SSI and Medicaid eligibility is destroyed. All financial gifts to the family for the child's benefit should be directed to the parents until a Special Needs Trust is established.
3. Establish a third-party Special Needs Trust immediately. Any financial support that family members — grandparents, aunts, uncles — want to provide for the child's lifetime care should flow into a properly structured SNT, not directly to the child. See the Inheritance Planning for Special Needs guide for how to coordinate family gifts correctly.
4. Apply for the HCBS physical disability waiver now. Waitlists in many states exceed 5 years. Applying at the time of diagnosis — years before the care need becomes urgent — is critical. See the HCBS Medicaid Waiver guide.

Equipment and care costs by SMA type

Equipment costs in SMA vary dramatically by type and disease course. The following reflects typical ranges for individuals receiving treatment who are living into adulthood:

These costs are in addition to — not instead of — the treatment costs covered by Medicaid. The SNT's purpose is to fund the supplemental layer that benefits don't reach: equipment upgrades beyond Medicaid's fee schedule rate, vehicle conversions that exceed VA or Medicaid grant limits, attendant hours beyond what a waiver covers, and quality-of-life expenses that are not categorized as medical necessity.

SNT sizing by scenario

The appropriate SNT corpus target varies dramatically by SMA type and whether an HCBS waiver slot is available:

These are starting points for SNT sizing conversations. Use the SNT Funding Calculator to model specific scenarios and the Lifetime Care Cost Calculator to project year-by-year costs. Both tools assume the Medicaid and HCBS waiver funding layers are maintained — if Medicaid access is disrupted, the required SNT corpus increases substantially to cover treatment costs directly.

Third-party SNT: structuring family gifts and estate plans

When parents, grandparents, or siblings want to leave assets for an SMA beneficiary, a third-party Special Needs Trust is the correct vehicle. Third-party SNTs:

• Do not count as a resource under SSI's $2,000 limit, preserving Medicaid
• Have no Medicaid payback requirement at death (unlike first-party d4A trusts)
• Can name other family members to receive remaining assets after the beneficiary dies
• Can hold life insurance, investments, real property, or retirement account proceeds

For SMA families with young children, the SNT is typically funded through the parents' life insurance — specifically, survivorship (second-to-die) life insurance when both parents are alive, or individual policies. The SNT should be the owner and beneficiary of any life insurance intended for the SMA beneficiary. See the Life Insurance for Special Needs Trusts guide for ownership structure, sizing, and the three-professional coordination model.

Estate plans for all family members — grandparents, aunts and uncles — should be reviewed to ensure no bequest names the SMA beneficiary directly. A $50,000 direct bequest to an SSI recipient destroys Medicaid immediately and requires a spend-down before eligibility can be restored. All planned gifts should route through the SNT. See the Inheritance Planning for Special Needs guide.

ABLE accounts for working SMA adults

For SMA Type 3 and Type 4 adults who receive SSI and work, an ABLE account — in combination with Section 1619(b) — creates a powerful flexibility layer that the SNT cannot provide. Key 2026 rules:⁹

• Age eligibility: disability onset before age 46. SMA Types 1–3, with childhood or early-adult onset, qualifies. Type 4 (onset after 30) qualifies only if onset was before 46.
• Annual contribution limit: $20,000 from all sources in 2026.
• ABLE-to-Work: SMA adults who work can contribute an additional $15,650 from their own earned income in 2026. This shelters earned income from the SSI resource limit while funding disability-related expenses directly.
• Qualified disability expenses for SMA include: accessible transportation and vehicle maintenance, wheelchair servicing and supplies, home modifications, medical equipment co-pays, and health-related therapy not covered by insurance.

The ABLE account gives the beneficiary direct access to disability funds without requiring trustee approval for every expenditure — ideal for day-to-day disability costs like wheelchair servicing, accessible rideshare, and therapy co-pays. The SNT handles larger capital expenditures (vehicle conversion, home modification, equipment replacement) where trustee coordination adds appropriate oversight. The two accounts are designed to work together, not to replace each other. See the SNT vs ABLE Account comparison and the ABLE Account 2026 guide for full rules.

Insurance for SMA Type 4 adults: the GINA gap

SMA Type 4 typically presents as progressive weakness in adulthood in individuals who were otherwise healthy throughout early life. Some families carry a known SMN1 deletion in a parent with Type 4 and are aware their children may develop symptoms. This creates a planning window that closes with symptom progression:

• GINA (Genetic Information Nondiscrimination Act) does NOT protect life insurance or long-term disability insurance. It only covers health insurance and employment. An individual who undergoes genetic testing that confirms an SMN1 mutation can legally be declined life insurance or charged rated premiums based on that information.
• Life and LTD insurance should be applied for and secured before genetic testing or before symptoms become clinically documented. Once clinical SMA is diagnosed, insurer underwriting will reflect the prognosis. Once symptoms progress to the point where function is significantly impaired, the window for obtaining standard-rate coverage closes.
• Long-term care (LTC) insurance is unlikely to be insurable at standard rates for anyone with a confirmed SMA diagnosis. Alternative LTC funding strategies — cash value life insurance with LTC riders, self-funded reserving through the SNT or taxable investments — should be modeled early.

Priority actions for SMA families

1. Enroll in Medicaid immediately after diagnosis. For infants diagnosed via newborn screening, apply for SSI and Medicaid before the treatment decision is made. The cash benefit may be $0 based on parental income, but Medicaid eligibility is separate from the SSI cash amount in most states. A benefits counselor and a special needs attorney should be engaged within weeks of diagnosis.
2. Establish a Special Needs Trust before any financial gifts arrive. Family members who want to contribute financially should be directed to the SNT — not to UTMA accounts, 529 accounts, or direct gifts in the child's name. A grandparent's $50,000 gift to the child directly destroys SSI and Medicaid. The same $50,000 into the SNT preserves every benefit.
3. Apply for the HCBS physical disability waiver immediately. Waitlists range from 1 to 10+ years in many states. Applying early is the only way to be in the queue when care needs intensify. Types 1 and 2 families should apply at the time of diagnosis, not when the child transitions to adult services at 18.
4. File SSI/SSDI as early as possible for Types 0/1. The CAL process takes approximately 10 days with documentation. Every month of delayed filing is a month of delayed benefits and a month of delayed Medicaid establishment.
5. Understand Section 1619(b) before the first raise. SMA Type 3 adults who work and receive SSI should understand their state's 1619(b) threshold before accepting any earnings increase that approaches the threshold. A WIPA counselor can calculate the individualized threshold and confirm the Medicaid-protection ceiling before it becomes an emergency.
6. Review all beneficiary designations in the parent's estate plan. Every IRA, 401(k), life insurance policy, and will that currently names the SMA beneficiary directly must be redirected through the SNT. See the Retirement Accounts and Special Needs guide.
7. SMA Type 4 adults: secure life and LTD insurance before symptoms progress. The GINA gap means confirmed genetic test results can affect underwriting for these products. Act before diagnosis is clinical, not after.

Sources

1. Cure SMA — SMA Facts and Statistics. SMA is caused by a deletion or mutation in the survival motor neuron 1 (SMN1) gene. SMA Type 1 (Werdnig-Hoffmann): onset birth to 6 months, never achieves independent sitting without treatment, historically the leading genetic cause of infant death. SMA Type 2 (Dubowitz): onset 6–18 months, achieves sitting but not standing. SMA Type 3 (Kugelberg-Welander): onset after 18 months, achieves ambulation at some point. SMA Type 4: adult onset, mild. SMA added to Recommended Uniform Screening Panel (RUSP) in July 2018; all 50 states + DC screen for SMA as of 2026. Scoliosis prevalence in SMA Type 2: approximately 50–60%.
2. Biogen — Spinraza (nusinersen). FDA approved December 2016 for all SMA types and all ages. Intrathecal delivery every 4 months after loading series. List price: approximately $125,000 per injection; 6 loading doses in year 1 (~$750,000); 3 maintenance doses per year thereafter (~$375,000/year). Biogen offers SMA360° financial assistance program for eligible patients. Actual cost varies by payer; Medicaid and commercial insurance typically cover with prior authorization. Prices as reported by Biogen, GoodRx, and healthcare cost databases for 2025–2026.
3. Genentech/PTC Therapeutics — Evrysdi (risdiplam). FDA approved August 7, 2020, for SMA types 1, 2, and 3 in patients 2 months and older. Oral liquid suspension taken daily at home. Weight-based pricing capped at $340,000/year for patients at or above approximately 44 pounds; lower annual cost for lighter patients. Genentech co-pay assistance available for commercially insured patients up to $25,000/year. Prices as reported by Genentech and healthcare cost databases for 2025–2026.
4. FDA — Approval of Itvisma (onasemnogene abeparvovec-brve). FDA approved November 24, 2025, for patients ages 2 years and older with confirmed SMN1 gene mutation. Intrathecal administration, single fixed dose not adjusted for weight or age. Wholesale acquisition cost: $2.59 million. Based on Phase 3 STEER and open-label STRENGTH studies demonstrating statistically significant improvements in motor function. Distinct from original Zolgensma (onasemnogene abeparvovec-xioi), approved May 2019 for patients under 2 years, IV administration, list price $2.125 million. Novartis offers outcomes-based payment program spreading cost over 5 annual installments of approximately $518,000.
5. SSA — Complete List of Compassionate Allowances Conditions. Spinal Muscular Atrophy Types 0 and 1 are included on the CAL list. As of August 2025, the CAL list includes 300 conditions total. CAL enables disability determination in approximately 10 days with sufficient medical documentation including genetic confirmation of SMN1 deletion/mutation. CAL is not automatic; the applicant must file a claim and provide documentation. Types 2, 3, and 4 are not on the CAL list and are evaluated under standard processing with functional criteria under Section 11.00 of the SSA Blue Book.
6. SSA Blue Book — 11.00 Neurological Disorders (Adult). Motor neuron disorders other than ALS — including SMA Types 2 and 3 — are evaluated for effects on motor functioning, bulbar and neuromuscular functioning, respiratory function, and physical and mental limitations rather than under a single specific listing number. Standard processing time: 3–6 months. Functional capacity assessment based on documented motor deficits, respiratory involvement, and ability to perform sedentary work tasks. Listing 11.10 applies to ALS specifically and does not cover SMA.
7. SSA — Disabled Adult Child (DAC) Benefits. An adult whose disability began before age 22 may receive Social Security benefits on a parent's earnings record when the parent retires, becomes disabled, or dies. DAC benefit: 50% of parent's PIA (parent living and receiving retirement or disability benefits); 75% of PIA (parent deceased). Triggers Medicare after 24-month waiting period. SSDI SGA $1,690/month (non-blind, 2026). SSI FBR $994/month (2026). DAC income may reduce SSI cash benefit but Section 1619(b) can protect Medicaid when DAC income exceeds SSI break-even point but falls below state threshold.
8. SSA POMS SI 02302.200 — 1619(b) Charted Threshold Amounts (updated 01/20/2026). Section 1619(b) allows SSI recipients to retain Medicaid coverage when earnings exceed SSI payment level, provided earnings remain below the state threshold. 2026 state thresholds range from $29,412 (Northern Mariana Islands) to $84,208 (Minnesota). Continental US thresholds for most states fall in the $35,000–$55,000 range; states with higher Medicaid costs (CT, MA, NY, CA) have higher thresholds. Individualized threshold available for beneficiaries with high impairment-related work expenses, publicly funded attendant care, or medical costs exceeding the state average. SGA 2026: $1,690/month non-blind; $2,830/month blind.
9. ABLE National Resource Center — 2026 Contribution Limits and Eligibility. Annual ABLE contribution limit: $20,000 from all sources (2026). ABLE-to-Work additional contribution: up to $15,650 from beneficiary's own earned income (federal poverty level for one-person household, 2026). Age eligibility: disability onset before age 46, effective January 2026 (ABLE Age Adjustment Act). SSI protection: ABLE account balance up to $100,000 does not count toward SSI's $2,000 resource limit. Qualified disability expenses include transportation, housing, education, health, employment, assistive technology, and personal support services.

Rules verified against 2026 SSA, FDA, and ABLE standards. SSI FBR $994/month (2026). SSDI SGA $1,690/month; TWP trigger $1,210/month (2026). ABLE contribution limit $20,000/year; ABLE-to-Work additional $15,650/year; age eligibility onset before 46 (all 2026). Section 1619(b) thresholds per SSA POMS SI 02302.200 updated January 2026. Spinraza list price $375,000/year maintenance per Biogen. Evrysdi list price $340,000/year cap per Genentech. Itvisma list price $2.59M per Novartis, FDA approval November 24, 2025. Equipment cost ranges are estimates from rehabilitation and SMA specialty sources; actual costs vary. SNT corpus targets are illustrative based on care scenario assumptions and are not guarantees of adequacy.